Stockscreener 앱 받기
0.8825
2.08%
-0.0187
시간 외 거래:
.90
0.0175
+1.98%
전일 마감가:
$0.9012
열려 있는:
$0.9049
하루 거래량:
80,209
Relative Volume:
0.03
시가총액:
$1.74M
수익:
$644.60K
순이익/손실:
$-9.87M
주가수익비율:
-0.00105
EPS:
-837.9618
순현금흐름:
$-9.02M
1주 성능:
+5.31%
1개월 성능:
-4.12%
6개월 성능:
-79.71%
1년 성능:
-95.54%
1일 변동 폭
$0.8825
$0.91
1주일 범위
$0.81
$0.9502
52주 변동 폭
$0.7846
$19.75
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
BDRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
0.8825 | 4.55M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-08 | 개시 | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr 주식(BDRX)의 최신 뉴스
Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - TipRanks
Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change Effective July 31, 2025 - Nasdaq
Biodexa Pharmaceuticals to implement 1:10 ADR ratio change - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change from 1:10 to 1:100,000. - AInvest
MFS Extends Deadline for Liquidity Event for MFS Investment Grade Municipal Trust - AInvest
ADR Ratio Change - GlobeNewswire
Biodexa Plans Major ADR Restructuring: 1:10 Reverse Split to Meet Nasdaq Requirements - Stock Titan
Biodexa files European clinical trial application for FAP treatment By Investing.com - Investing.com India
Biodexa files European clinical trial application for FAP treatment - Investing.com
Biodexa's $20M-Backed Phase 3 Trial for Rare Cancer Prevention Drug Expands to Europe - Stock Titan
SMX (Security Matters) Plc (SMX) Stock: Navigating Drops and Gains - investchronicle.com
Company’s Banking Stock: Dissecting a 60.04% Quarterly Revenue Decline Amid Growth - investchronicle.com
Results of Annual General Meeting - GlobeNewswire
Biodexa's $20M-Backed Phase 3 Trial for Rare Genetic Disease FAP Begins Patient Enrollment - Stock Titan
Biodexa Unveils Phase 3 FAP Trial "Serenta": New Hope for Rare Disease Patients - Stock Titan
Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com
Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals changes share nominal value - Investing.com
Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India
Biodexa shareholders approve all resolutions at general meeting - Investing.com
Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells - Stock Titan
Biodexa secures additional $3M for cancer drug trial By Investing.com - Investing.com India
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan
Biodexa secures additional $3M for cancer drug trial - Investing.com
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here - sharewise
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Biodexa Pharmaceuticals adjusts warrant exercise price - Investing.com
Biodexa Pharmaceuticals adjusts warrant exercise price By Investing.com - Investing.com India
Biodexa gains orphan drug status in EU for colon disease treatment - Investing.com
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewswire
Result of General Meeting - GlobeNewswire
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN
Biodexa Shareholders to Vote on Strategic Share Subdivision Plan: Key Meeting Details Revealed - Stock Titan
Biodexa Annual Results Reveal Clinical-Stage Pipeline Expansion Strategy - Stock Titan
Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - BioSpace
Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India
Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Yahoo Finance
Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart
Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News
Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater
Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater
Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - GlobeNewswire
AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater
Biodexa Pharmaceuticals Plc Adr (BDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.91%
0.25%
자본화:
|
볼륨(24시간):